KAZIA’S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY...

KAZIA’S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY
SIGNALS IN PRECLINICAL MODELS OF MELANOMA
Sydney, 27 October 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data from an ongoing research collaboration with the Huntsman Cancer Institute at the
University of Utah in Salt Lake City, UT.
A poster presentation by Dr Gennie Parkman and colleagues, working in the laboratory of Professor Sheri Holmen, has shown paxalisib to be active in vitro and in vivo against a range of preclinical models of metastatic melanoma, the most aggressive form of skin cancer. Dr Parkman’s data suggested substantial activity for paxalisib as monotherapy, and greater activity in combination with MEK and BRAF inhibitors, two classes of drugs that are commonly used for a substantial proportion of melanoma patients.
“This is among the most promising single agent data that we have seen in our research,” commented Professor Sheri Holmen, lead investigator on the project. “Despite the widespread adoption of immunotherapy in recent years, there remains substantial unmet need in melanoma, particularly in those patients who develop brain metastases. We look forward to exploring the potential of paxalisib further in our research, and hopefully seeing
the drug transition to a clinical trial in the near future.”
A copy of Dr Parkman’s poster is available via the Kazia website:

https://www.kaziatherapeutics.com/site/pdf/1a6a7cef-bde8-42b0-91c7-e5db0f658838/Poster-at-Int-Congress-of-the-Society-for-Melanoma-Research.pdf